Nephroprotection via SGLT2 inhibition

被引：0

作者：

Wanner, C. ^{[1
]}

机构：

[1] Univ Klinikum Wurzburg, Schwerpunkt Nephrol, Med Klin & Poliklin 1, Oberdurrbacherstr 6, D-97070 Wurzburg, Germany

来源：

DIABETOLOGE | 2018年 / 14卷 / 02期

关键词：

Chronic kidney diseases; Diabetes mellitus; Diabetic kidney disease; Diabetic nephropathies; ESRD; ESTABLISHED CARDIOVASCULAR-DISEASE; EMPAGLIFLOZIN; OUTCOMES;

D O I：

10.1007/s11428-018-0314-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Renal effects of empagliflozin and canagliflozin. In 2016 and 2017, two major outcomes studies, the EMPA-REG OUTCOME trial (EMPA-REG OUTCOME: Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) and CANVAS (Canagliflozin Cardiovascular Assessment Study-Renal Endpoints), with the sodium-glucose cotransporter 2 (SGLT2) inhibitors empagliflozin and canagliflozin-both of which had renoprotective effects with regard to progression of diabetic kidney disease-were published. Analyses of the EMPA-REG OUTCOME trial showed that empagliflozin significantly reduced cardiovascular and renal endpoints not only in patients with an estimated glomerular filtration rate (eGFR) > 60ml/min/1.73m(2) but also in patients with prevalent kidney disease and an eGFR of 30-60ml/min/1.73m(2).

引用

页码：93 / 95

页数：3

共 7 条

[1] Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial [J].

Cherney, David Z. I. ;

Zinman, Bernard ;

Inzucchi, Silvio E. ;

Koitka-Weber, Audrey ;

Mattheus, Michaela ;

von Eynatten, Maximilian ;

Wanner, Christoph .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08) :610-621

[2] Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus [J].

Cherney, David Z. I. ;

Perkins, Bruce A. ;

Soleymanlou, Nima ;

Maione, Maria ;

Lai, Vesta ;

Lee, Alana ;

Fagan, Nora M. ;

Woerle, Hans J. ;

Johansen, Odd Erik ;

Broedl, Uli C. ;

von Eynatten, Maximilian .

CIRCULATION, 2014, 129 (05) :587-597

[3] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J].

Neal, Bruce ;

Perkovic, Vlado ;

Mahaffey, Kenneth W. ;

de Zeeuw, Dick ;

Fulcher, Greg ;

Erondu, Ngozi ;

Shaw, Wayne ;

Law, Gordon ;

Desai, Mehul ;

Matthews, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) :644-657

[4] A new era in therapeutics for diabetic kidney disease [J].

Wanner, Christoph .

NATURE REVIEWS NEPHROLOGY, 2018, 14 (02) :78-+

[5] Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease [J].

Wanner, Christoph ;

Lachin, John M. ;

Inzucchi, Silvio E. ;

Fitchett, David ;

Mattheus, Michaela ;

George, Jyothis ;

Woerle, Hans J. ;

Broedl, Uli C. ;

von Eynatten, Maximilian ;

Zinman, Bernard ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. ;

Mortelmans, J. .

CIRCULATION, 2018, 137 (02) :119-129

[6]

Wanner C, 2016, NEW ENGL J MED, V375, P323, DOI [10.1056/NEJMoa1515920, 10.1056/NEJMc1611290]

[7] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [J].

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Fitchett, David ;

Bluhmki, Erich ;

Hantel, Stefan ;

Mattheus, Michaela ;

Devins, Theresa ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) :2117-2128

← 1 →